Zydus Lifesciences Limited — Updates, 04-03-2025: Press Release

Zydus Lifesciences Limited is embarking on a pioneering project to develop the world’s first combination vaccine targeting both shigellosis and typhoid, with backing from the Gates Foundation. This initiative, set to kick off in March 2025, entails early-stage development, animal immunogenicity studies, and regulatory preclinical toxicology assessments. The vaccine aims to protect children under five, challenging the dual threat posed by these deadly enteric diseases, particularly in endemic regions.

The company's collaboration with a research partner will utilize Zydus’ WHO prequalified Typhoid conjugate vaccine and a Shigella vaccine from its partner. The introduction of this combination vaccine addresses critical public health needs, especially as immunization schedules become increasingly complex and costly. This initiative not only underscores Zydus’ innovation capabilities but also aligns with efforts to enhance global public health outcomes. Investors should monitor this collaboration closely as it has the potential to create a significant impact in childhood disease prevention and represent a strategic growth opportunity for Zydus.